Trade Summary

Yesterday, Siegall Clay B, serving as Pres, CEO at Immunome Inc. (IMNM), purchased 4,729 shares at $21.15 per share, for a total transaction value of $100,018.00. Following this transaction, Siegall Clay B now holds 665,254 shares of IMNM.

This purchase represents a 1.00% increase in Siegall Clay B's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, December 30, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 30, 2025, meaning the disclosure happened on the same day as the trade.

Immunome Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.